IL13 and Alzheimer disease: The introduction of dupilumab, which targets the interleukin-4 receptor α and interleukin-13 and is administered subcutaneously every two weeks to individuals aged 12 and older with moderate-to-severe AD not well managed by topical prescription medications or for whom those therapies are not recommended, has altered the AD therapy model in the past four years [71].